2,452 results on '"Kapoor, Prashant"'
Search Results
2. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome: MULTIPLE MYELOMA, GAMMOPATHIES
3. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
4. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
5. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms
6. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
7. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
8. Mode of progression in smoldering multiple myeloma: a study of 406 patients
9. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
10. Prognostic impact of patient-reported symptoms in multiple myeloma
11. Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes
12. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
13. Retreatment of multiple myeloma with previously refractory drugs
14. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
15. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
16. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
17. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
18. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
19. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia
20. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
21. Current approach to Waldenström macroglobulinemia
22. Muscle and fat composition in patients with newly diagnosed multiple myeloma
23. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
24. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
25. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
26. Utility of flow cytometry screening before MRD testing in multiple myeloma
27. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
28. Conditional survival in multiple myeloma and impact of prognostic factors over time
29. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
30. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
31. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
32. Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia
33. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy
34. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
35. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
36. Outcomes after biochemical or clinical progression in patients with multiple myeloma
37. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
38. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
39. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma.
40. Autologous and Allogeneic Stem‐Cell Transplantation for Transformed Waldenström Macroglobulinemia.
41. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
42. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
43. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
44. Kidney Transplant Outcomes of Patients With Multiple Myeloma
45. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant
46. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
47. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)–Associated Lesions: A Case Series
48. Current approach to Waldenström Macroglobulinemia
49. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
50. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.